Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)

NCT02060370 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Genitourinary Cancer
Kidney Cancer

Interventions

DRUG: Sunitinib
BEHAVIORAL: Questionnaire

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]